As the Ebola outbreak continues to claim victims in West Africa, governments and industry alike are racing toward a therapeutic or preventive drug that could help halt its deadly spread and avert future human crises involving the virus.
Scripps Research Institute is developing a passive vaccine to treat cocaine overdose and has seen promising results in animals.
Part of the success of some cancers is that they can avoid an immune response, and this can also cut the response to vaccines. Immunovaccine is developing a comeback to this--suppress the suppression.
Halifax, Nova Scotia-based Immunovaccine will focus the Phase I/II clinical development plan for DPX-Survivac on ovarian cancer. The decision is based on positive input from leaders in cancer